Eli Lilly and Company (Lilly) said that it will start the rollout of the Tempo Personalized Diabetes Management Platform, the company’s first connected platform, later this year in the US.

The platform is expected to help adult patients having type 1 or type 2 diabetes and clinicians make decisions that are informed and data-backed for the management of treatment with Lilly’s insulins.

According to the firm, the technology consists of three key parts, which include the Tempo Smart Button, a compatible TempoSmart app, and a prefilled Tempo Pen. The three components combine to provide personalised guidance for adults having diabetes.

The Tempo Smart Button was approved by the US Food and Drug Administration (FDA) in September this year, Lilly said.

The TempoSmart app was developed by the pharma major in collaboration with Welldoc. It is a private-label version of the latter’s BlueStar diabetes management app.

TempoSmart is customised to collect information about insulin doses from the Tempo Smart Button.

Lilly diabetes connected care head Kevin Cammack said: “Lilly has over a century of knowledge of insulin and its complexities, and recognizes the emotional impact of managing diabetes.

“Launching this platform is an opportunity for us to more broadly support those who rely on our insulins.”

Lilly said that the reusable Tempo Smart Button attaches to the top of Tempo Pen, its prefilled, disposable insulin pen. The functions of the Smart Button are to detect, store, and transfer insulin dose-related data to the compatible app via Bluetooth technology.

The TempoSmart app will record insulin dose data and enable data sharing between patients and healthcare providers.

The pharmaceutical firm mentioned that insulin dose information and advanced features are accessible to adults with diabetes through TempoSmart. The app sends medication reminders, personalised education resources, and feedback on levels of blood glucose.

It also enables integration with Dexcom Continuous Glucose Monitoring (CGM) Systems and Tempo Blood Glucose Monitor (BGM) as well as other compatible BGMs.

TempoSmart is also designed to sync data with wearable devices from Fitbit, Google Fit, Garmin, and the Apple Health app, Lilly said.

The company will execute the rollout of the platform in a phased manner to a few clinics, with a national launch anticipated for next year.